Since the patient refused bone marrow evaluation, she was initially treated with erythropoietin therapy based on the assumption that she may have an underlying refractory anemia associated with myelodysplastic syndrome or anemia of chronic disease. This evidence concerns the gene EPO and myelodysplastic syndrome.